HAYA Therapeutics is a Swiss precision therapeutics company that has developed tools and methods to interrogate lncRNA biology to design tissue- and cell-type-specific genomic medicines. GEN Edge talked to Samir Ounzain, PhD, co-founder and CEO of HAYA Therapeutics, at BIO 2022 in San Diego to catch up on how the company is carving the path to commercializing lncRNA-targeting medicines . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge